Volume 28, Number 9—September 2022
Research
Rapid Adaptation of Established High-Throughput Molecular Testing Infrastructure for Monkeypox Virus Detection
Dominik Nörz, Hui Ting Tang, Petra Emmerich, Katja Giersch, Nicole Fischer, Stephan Schmiedel, Marylyn M. Addo, Martin Aepfelbacher, Susanne Pfefferle, and Marc Lütgehetmann
Table 2
Software settings for run protocol for a dual-target MPXV assay rapidly adapted from established high-throughput molecular testing infrastructure*
| Protocol setting |
Channel setting, use |
||||
|---|---|---|---|---|---|
| 1, Not used |
2, Monkeypox |
3, Nonvariola |
4, Not used |
5, Internal control |
|
| Relative fluorescence increase |
NA |
2 |
2 |
NA |
2 |
| PCR cycling conditions | UNG incubation | Pre-PCR step | 1st measurement | 2nd measurement | Cooling |
| No. cycles | Predefined | 1 | 5 | 45 | Predefined |
| No. steps | Predefined | 3 | 2 | 2 | Predefined |
| Temperature | Predefined | 55°C; 60°C; 65°C | 95°C; 55°C | 91°C; 58°C | Predefined |
| Hold time | Predefined | 120 s; 360 s; 240 s | 5 s; 30 s | 5 s; 25 s | Predefined |
| Data acquisition | Predefined | None | End of each cycle | End of each cycle | Predefined |
*Protocol was run on 400 µL swab samples. Protocol adapted for cobas omni Utility Channel (Roche Diagnostics, https://diagnostics.roche.com). Relative fluorescence increase thresholds were used for automated result calls. NA, not applicable; UNG, uracyl-N-glycosylase.
Page created: July 13, 2022
Page updated: August 19, 2022
Page reviewed: August 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.